Literature DB >> 16502004

Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.

Samuel Vokurka1, Eva Bystrická, Vladimír Koza, Jana Scudlová, Vladislava Pavlicová, Dana Valentová, Maria Visokaiová, Lubica Misaniová.   

Abstract

Study on the normal saline vs povidone-iodine mouthwashes for oral mucositis (OM) prophylaxis in patients after high-dose chemotherapy comprising bischloroethyl nitrosourea etoposide ara-C melphalan (BEAM) or high-dose melphalan (HD-L-PAM) followed by autologous peripheral stem cell transplantation indicated that females have higher a incidence of OM compared to men, as reported by [Vokurka et al. 13:554-558, (2005)]. The multivariable analysis of larger cohort of 148 patients compliant with the original study protocol confirmed female gender to be an independent risk factor and predictor for OM. The HD-L-PAM (200 mg/m2) conditioning regimen revealed to be more toxic compared to BEAM as for incidence of OM grades 3-4 World Health Organization score. Body mass index, age, mouthwash solution used, and CD34+ cell number in the autologous graft were verified not to have an impact on OM incidence in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16502004     DOI: 10.1007/s00520-006-0031-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

1.  The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.

Authors:  Samuel Vokurka; Eva Bystrická; Vladimír Koza; Jana Scudlová; Vladislava Pavlicová; Dana Valentová; Jana Bocková; Lubica Misaniová
Journal:  Support Care Cancer       Date:  2005-03-30       Impact factor: 3.603

2.  Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases.

Authors:  J E Raber-Durlacher; N I Weijl; M Abu Saris; B de Koning; A H Zwinderman; S Osanto
Journal:  Support Care Cancer       Date:  2000-09       Impact factor: 3.603

Review 3.  Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.

Authors:  Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

4.  Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia.

Authors:  Kim Robien; Mark M Schubert; Barbara Bruemmer; Michele E Lloid; John D Potter; Cornelia M Ulrich
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

  4 in total
  17 in total

1.  Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.

Authors:  N Tandon; E Muchtar; S Sidana; A Dispenzieri; M Q Lacy; D Dingli; F K Buadi; S R Hayman; R Chakraborty; W J Hogan; W Gonsalves; R Warsame; T V Kourelis; N Leung; P Kapoor; S K Kumar; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2017-04-10       Impact factor: 5.483

Review 2.  Adverse event management of oral mucositis in patients with breast cancer.

Authors:  Sabine Seiler; Jens Kosse; Sibylle Loibl; Christian Jackisch
Journal:  Breast Care (Basel)       Date:  2014-04       Impact factor: 2.860

3.  The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies.

Authors:  Y-K Chen; H-A Hou; J-M Chow; Y-C Chen; P-R Hsueh; H-F Tien
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

4.  Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors.

Authors:  Stefan Wuketich; Stefan A Hienz; Christine Marosi
Journal:  Support Care Cancer       Date:  2011-02-18       Impact factor: 3.603

Review 5.  Management of oral mucositis in patients who have cancer.

Authors:  Rajesh V Lalla; Stephen T Sonis; Douglas E Peterson
Journal:  Dent Clin North Am       Date:  2008-01

6.  Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy.

Authors:  Velia Ramírez-Amador; Gabriela Anaya-Saavedra; Erick Crespo-Solís; Esther Irigoyen Camacho; Imelda González-Ramírez; Sergio Ponce-de-León
Journal:  Support Care Cancer       Date:  2009-08-06       Impact factor: 3.603

7.  Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Authors:  Per Boye Hansen; Milena Penkowa
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603

8.  Patterns of sore mouth in outpatients with cancer receiving chemotherapy.

Authors:  Carlton G Brown; Susan L Beck; Douglas E Peterson; Deborah B McGuire; William N Dudley; Kathleen H Mooney
Journal:  Support Care Cancer       Date:  2008-10-07       Impact factor: 3.603

9.  Are orange lollies effective in preventing nausea and vomiting related to dimethyl sulfoxide? A multicenter randomized trial.

Authors:  Silvia Gonella; Paola Berchialla; Benedetto Bruno; Paola Di Giulio
Journal:  Support Care Cancer       Date:  2014-04-04       Impact factor: 3.603

10.  Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.

Authors:  Mustafa Ozturk; Seref Komurcu; Selim Kilic; Ahmet Ozet; Fikret Arpaci; Bekir Ozturk; Okan Kuzhan; Selmin Ataergin
Journal:  Support Care Cancer       Date:  2009-02-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.